Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
To The Editor: The study by Dr Cushman and
colleagues1 is based on data from the WHI and
details of the methods are reported in an earlier JAMA publication.2 The prior study notes that of the 8506 participants
in the CEE + MPA group, 3444 (40.5%) were unblinded for control of vaginal
bleeding. Further, CEE and/or MPA doses could have been altered for treatment
of this condition, yet no published data from this trial have indicated the
effect that this treatment had on the study outcomes. It seems inaccurate
to label this a blinded controlled trial of placebo against CEE + MPA.
Blackwell RE. Estrogen Plus Progestin and Risk of Venous Thrombosis. JAMA. 2005;293(11):1322–1323. doi:10.1001/jama.293.11.1322-b